Cannabis Therapeutics and the Future of Neurology

Author: Ethan B. Russo Published in: Frontiers in Integrative Neuroscience  October 2018 Abstract Introduction: Cannabis burst across the Western medicine horizon after its introduction by William O’Shaughnessy in 1838 (O’Shaughnessy, 1838–1840;…

Cannabinoid Effects on Experimental Colorectal Cancer Models Reduce Aberrant Crypt Foci (ACF) and Tumor Volume: A Systematic Review

Author: Eduardo Orrego-González, Luisa Londoño-Tobón, José Ardila-González, Diego Polania-Tovar, Ana Valencia-Cárdenas and Alberto Velez-Van Meerbeke Published in Hindawi July 2020 Abstract Objectives Colorectal cancer represents a heavy burden for health systems…

Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid

Authors: Francesca Borrelli, Ester Pagano, Barbara Romano, Stefania Panzera, Francesco Maiello, Diana Coppola, Luciano De Petrocellis, Lorena Buono, Pierangelo Orlando, Angelo A. Izzo Published in Oxford Academic September 2014 Abstract Cannabigerol…

The effect of concomitant cannabinoids during immune checkpoint inhibitor treatment of advanced stage malignancy.

Authors: Adam Biedny, Susan Szpunar, Ahmed Abdalla, Zyad Kafri, Tarik H. Hadid Published in Journal of Clinical Oncology May 2020   Abstract Background: Immune checkpoint inhibitors are used in treatment…

Cannabidiol: Assessing preclinical safety in ovarian and endometrial carcinoma cell lines

Authors: Shannon Rush, Arvinder K Kapur, Manish S. Patankar, Lisa Marie Barroilhet Published in Journal of Clinical Oncology May 2020   Abstract Background: Cancer patients use cannabidiol (CBD) for chemotherapy…

Cannabinoids and hormone receptor-positive breast cancer treatment.

Authors: Luka Dobovišek, Fran Krstanović, Simona Borštnar, Nataša Debeljak
Cancers, 25 February 2020

Breast cancer (BC) is the most common cancer in women worldwide. Approximately 70-80% of BCs express estrogen receptors (ER), which predict the response to endocrine therapy (ET), and are therefore hormone receptor-positive (HR+). Endogenous cannabinoids together with cannabin…

Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.

Authors: Chao Liu, Sayed H. Sadat, Koji Ebisumoto, Akihiro Sakai, Bharat A. Panuganti, Shuling Ren, et al
Clinical Cancer Research, 13 January 2020

PURPOSE: Human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) is associated with daily marijuana use and is also increasing in parallel with increased marijuana use in the United States. Our study is designed to define the interaction between cannab…

Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement.

Authors: B. Whitcomb, C. Lutman, M. Pearl, E. Medlin, E. Prendergast, K. Robison, W. Burke
Gynecologic Oncology, 10 January 2020

Tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN) affect the human endocannabinoid system. Cannabinoids reduce chemotherapy induced nausea or vomiting (CINV) and neuropathic pain. Each state has its own regulations for medical and recreational cannabis use. Ef…

Concomitant Treatment of Malignant Brain Tumours With CBD – A Case Series and Review of the Literature.

Authors: Rudolf Likar, Markus Koestenberger, Martin Stultschnig, Gerhard Nahler
Anticancer Research, October 2019

Grade IV glioblastoma multiforme is a deadly disease, with a median survival of around 14 to 16 months. Maximal resection followed by adjuvant radiochemotherapy has been the mainstay of treatment since many years, although survival is only extended by a few months. In recent y…

Opportunities for cannabis in supportive care in cancer.

Authors: Amber S. Kleckner, Ian R. Kleckner, Charles S. Kamen, Mohamedtaki A. Tejani, et al
Therapeutic Advances in Medical Oncology, 1 August 2019

Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. However, the dearth of scientific evidence for the effectiveness of cannabis in treating these symp…

The heterogeneity and complexity of Cannabis extracts as antitumor agents.

Authors: Liran Baram, Ella Peled, Paula Berman, Ben Yellin, Elazar Besser, David Meiri, et al
Oncotarget, 25 June 2019

The Cannabis plant contains over 100 phytocannabinoids and hundreds of other components. The biological effects and interplay of these Cannabis compounds are not fully understood and yet influence the plant’s therapeutic effects. Here we assessed the antitumor effects of whole…

Should Oncologists Recommend Cannabis?

Authors: Donald I. Abrams
Current Treatment Options in Oncology, 3 June 2019

Cannabis is a useful botanical with a wide range of therapeutic potential. Global prohibition over the past century has impeded the ability to study the plant as medicine. However, delta-9-tetrahydrocannabinol (THC) has been developed as a stand-alone pharmaceutical initially …